Insulinoma: A Novel Presentation of Multiple Endocrine Neoplasia 4
AACE Clinical Case Reports · 2025-03 · 11 (2) · 93-97
DOI: 10.1016/j.aace.2024.11.009 ↗Kurz gefasst
Fallbericht in der Zeitschrift AACE Clinical Case Reports, 2025-03. Verfasst von Hye Jeong Han und 3 weiteren Autor:innen. Beteiligte Einrichtung: Division of Endocrinology, Diabetes, and Metabolism, Department of Medicine, University of Rochester Medical Center, Rochester, New York. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 10 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Background/Objective: Multiple endocrine neoplasia 4 (MEN4) is a rare syndrome caused by germline mutations in CKDN1B, and it shares clinical manifestations with MEN1, including primary hyperparathyroidism, pituitary adenomas, and pancreatic neuroendocrine tumors (NETs). The prevalence of MEN4 is
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Division of Endocrinology, Diabetes, and Metabolism, Department of Medicine, University of Rochester Medical Center, Rochester, New York.
- Department of Surgery, University of Rochester Medical Center, Rochester, New York.
- Department of Pathology, Massachusetts General Hospital, Boston, Massachusetts.
Zitieren
APA
Han, H. J., Moalem, J., Shih, A. R., & Gigliotti, B. J. (2025). Insulinoma: A Novel Presentation of Multiple Endocrine Neoplasia 4. AACE Clinical Case Reports, 11(2), 93-97. https://doi.org/10.1016/j.aace.2024.11.009
Vancouver
Han HJ, Moalem J, Shih AR, Gigliotti BJ. Insulinoma: A Novel Presentation of Multiple Endocrine Neoplasia 4. AACE Clinical Case Reports. 2025;11(2):93-97. doi:10.1016/j.aace.2024.11.009
BibTeX
@article{Han2025,
author = {Han, Hye Jeong and Moalem, Jacob and Shih, Angela R and Gigliotti, Benjamin J},
title = {Insulinoma: A Novel Presentation of Multiple Endocrine Neoplasia 4},
journal = {AACE Clinical Case Reports},
year = {2025},
volume = {11},
number = {2},
pages = {93--97},
doi = {10.1016/j.aace.2024.11.009}
}
EUVIMED